Accelerate Your Fibrosis Research

Effective in mice, failed in humans. Why? Prevent translational gaps in SSc drug discovery by choosing the right model (Bleomycin, HOCl, or Tsk) based on your drug's MOA. Includes a strategic decision matrix.

For researchers facing 'no reproducibility' or 'unexpected negative data' in preclinical studies. We explain failure causes from mismatch of model selection and evaluation systems, and introduce 3 re-evaluation strategies: STAM model, AI pathology, and PRO-C3.

'It worked in mice, but not in humans.' The key to crossing this valley of death is to evaluate with the same 'measure' as clinical trials. We explain how to utilize non-invasive biomarkers like FibroScan (CAP/VCTE), PRO-C3, and ELF score.